Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker S, Kruisselbrink AB, Briaire-de Bruijn IH, de Jong Y, van Wijnen AJ, Danen EHJ, Bovée JVMG.

Cancers (Basel). 2019 Dec 2;11(12). pii: E1918. doi: 10.3390/cancers11121918.

2.

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

3.

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.

Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG.

J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr.

4.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

5.

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.

van Balen P, van der Zouwen B, Kruisselbrink AB, Eefting M, Szuhai K, Jordanova ES, Falkenburg JHF, Jedema I.

Front Immunol. 2018 Feb 27;9:331. doi: 10.3389/fimmu.2018.00331. eCollection 2018.

6.

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.

de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG.

Transl Oncol. 2017 Aug;10(4):546-554. doi: 10.1016/j.tranon.2017.05.007. Epub 2017 Jun 24.

7.

Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.

Sand LGL, Buckle T, van Leeuwen FWB, Corver WE, Kruisselbrink AB, Jochemsen AG, Hogendoorn PCW, Szuhai K.

BMC Cancer. 2017 May 26;17(1):383. doi: 10.1186/s12885-017-3352-z.

8.

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

de Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JV.

Lab Invest. 2016 Oct;96(10):1128-37. doi: 10.1038/labinvest.2016.91. Epub 2016 Sep 12.

9.

Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.

van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I.

Biol Blood Marrow Transplant. 2014 Jun;20(6):760-9. doi: 10.1016/j.bbmt.2014.03.002. Epub 2014 Mar 7.

10.

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH.

Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18.

PMID:
23777765
11.

Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity.

van der Zouwen B, Kruisselbrink AB, Jordanova ES, Rutten CE, von dem Borne PA, Falkenburg JH, Jedema I.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1353-67. doi: 10.1016/j.bbmt.2012.06.017. Epub 2012 Jul 11.

12.

Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.

Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA, Marijt EW, Kruisselbrink AB, Frederik Falkenburg JH, Heemskerk MH.

Biol Blood Marrow Transplant. 2012 Feb;18(2):210-9. doi: 10.1016/j.bbmt.2011.10.018. Epub 2011 Oct 19.

13.

Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells.

Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE.

J Immunol. 2006 Aug 15;177(4):2080-7.

14.

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE.

Blood. 2006 Sep 15;108(6):2114-20. Epub 2006 May 11.

15.

Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit.

Nauta AJ, Kruisselbrink AB, Lurvink E, Mulder A, Claas FH, Noort WA, Willemze R, Fibbe WE.

Exp Hematol. 2005 Oct;33(10):1249-56.

PMID:
16219548
16.

Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice.

in 't Anker PS, Noort WA, Kruisselbrink AB, Scherjon SA, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE.

Exp Hematol. 2003 Oct;31(10):881-9.

PMID:
14550803
17.

Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential.

in 't Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, van Bezooijen RL, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE.

Haematologica. 2003 Aug;88(8):845-52.

18.

Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice.

Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MH, Löwik CW, Falkenburg JH, Willemze R, Fibbe WE.

Exp Hematol. 2002 Aug;30(8):870-8.

PMID:
12160838

Supplemental Content

Loading ...
Support Center